Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia.

摘要: PURPOSETo quantify the incidence and severity of tumor lysis syndrome (TLS) as a consequence fludarabine therapy in patients with advanced chronic lymphocytic leukemia (CLL).PATIENTS AND METHODSA retrospective review questionnaire follow-up clinical laboratory data were performed on intermediate or high-risk CLL National Cancer Institute Group C protocol special exception mechanisms, phase II trials fludarabine, for whom adverse drug reports TLS available. Fludarabine was administered at dose 20 to 40 mg/m2 per day 5 days monthly intervals.RESULTSAmong 6,137 patients, suspected 26 (0.42%), features consistent present (0.33%). Prophylaxis against had been 60% these patients. Clinical similar who did not develop TLS. Of TLS, 90% CLL, 60 months prior disease duration, median pretreatm...